Condition: IgA Nephropathy · Sponsor: Guangdong Provincial People's Hospital
IgAN is the most prevalent primary glomerulonephritis in China, is characterized by the deposition of IgA1 (particularly, galactose-deficient IgA1) in the glomerular mesangium. Galactosedeficient IgA1, supposed to be produced by Peyer patches in the mucosa-associated lymphoid tissue (MALT), is triggered by exposure to commensal or pathogenic bacteria, involved in the initial step in the pathogenesis of IgAN. Similar to intestinal flora, a disruption in oral flora is closely associated with the occurrence of many malignant tumors and autoimmune diseases. The relationship between oral and throat microflora and the occurrence of IgAN is unclear at present. The aim of the present study was to develop a preliminary model based on mucosa -specific microbes and clinical indicators to facilitate the early diagnosis of IgAN and obtain insights into its treatment.
This description comes directly from the study's public registry record.
Xueqing Yu · +86-20-83827812 · yuxq@mail.sysu.edu.cn
Fengtao Cai · 19860209072 · fengtaoc@126.com
Always discuss trial participation with your own doctor first.
| Sun Yat-sen Memorial Hospital Sun Yat-sen university | Guangzhou, Guangdong, China | Recruiting |
| The Third Affiliated Hospital of Southern Medical University | Guangzhou, Guangdong, China | Recruiting |
| The Third Affiliated Hospital of Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| Guangdong Provincial People's Hospital | Guanzhou, Guangdong, China | Recruiting |
| The First Affiliated Hospital of Sun Yat-sen University | Guanzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05190848